INTeRCePT3.0

Spatial and Molecular Characterization of Lymphomas

INTeRCePT 3.0 investigates the molecular composition and spatial organization of lymphomas using high-resolution single-cell and multi-omics technologies. These approaches enable detailed analysis of tumor tissue at single-cell resolution and capture both the architecture of the tumor microenvironment and the interactions between tumor cells and the immune system. Integrated analyses provide the foundation for precisely understanding tumor-biological mechanisms and functional relationships, and for translating these insights into predictive models.

Longitudinal Analysis of Tumor and Immune Dynamics

More than 1,000 tumor and blood samples are being analyzed longitudinally — collected before treatment and especially during the early phases of therapy. These repeated measurements allow systematic tracking of changes in tumor and immune profiles over time and enable the identification of early indicators of insufficient treatment response.

In addition, liquid biopsies are used to analyze circulating tumor DNA (ctDNA), enabling continuous and minimally invasive monitoring of genetic tumor alterations. This approach allows early detection of emerging resistance mechanisms and supports timely adaptation of treatment strategies.

Analysis of Immune Responses During Therapy

Another major focus is high-dimensional immune profiling, which enables detailed investigation of the composition and function of the immune system throughout treatment. Changes in different immune cell populations and their activation states are assessed longitudinally and correlated with clinical outcomes. The goal is to better understand immune responses to different therapies and to integrate immunological parameters into the prediction of treatment success.

Development of Predictive Models and Dynamic Risk Prediction

To integrate the various molecular, cellular, and clinical data types, quantitative models and machine learning approaches are employed. These methods enable systematic analysis of complex relationships between tumor biology, immune responses, and treatment outcomes.

Based on these analyses, INTeRCePT 3.0 develops individualized models for dynamic risk prediction designed to support more precise and adaptive treatment strategies. The resulting models will subsequently be validated in a prospective clinical study to demonstrate the feasibility of dynamic precision oncology approaches in lymphoma care.